The International Parkinson and Movement Disorders Society (MDS) 2026 meeting highlighted remarkable advances in disease-modifying therapies for Parkinson's disease (PD) and Huntington's disease (HD). This page captures key developments across five major therapeutic frontiers:
- Gene therapy advances
- Cell replacement therapies
- Novel disease-modifying agents
- Deep brain stimulation innovations
- Digital therapeutics and wearables
AAV (Adeno-Associated Virus) vectors remain the dominant platform for CNS gene therapy:
| Vector |
Target |
Approach |
Status |
| AAV2-AADC |
Striatal AADC |
Aromatic L-amino acid decarboxylase restoration |
Phase II |
| AAV-GAD |
Subthalamic GAD67 |
GABA synthesis enhancement |
Phase I/II |
| AAV-NTN |
GDNF |
Neurotrophic factor delivery |
Preclinical |
The latest trials focus on optimized serotypes (AAV2.7m8, AAV-PHP.B) with improved CNS penetration and reduced immunogenicity.
Gene editing approaches are moving toward clinical translation:
- GBA mutations: CRISPR correction in patient-derived iPSCs shows promise
- LRRK2: Allele-specific silencing in development
- SNCA: Alpha-synuclein reduction via gene silencing
| Factor |
Vector |
Mechanism |
Clinical Stage |
| GDNF |
AAV2 |
Dopaminergic protection |
Phase I |
| AAV-NRTN (Neurturin) |
AAV |
TrkB activation |
Phase II |
| CDNF |
AAV |
MANF family neurotrophic |
Preclinical |
Cell replacement has advanced significantly:
| Cell Source |
Approach |
Advantages |
Challenges |
| fetal VM |
Primary mesencephalic tissue |
Clinical history |
Ethical/sourcing |
| iPSC-derived |
Patient-derived DA neurons |
Unlimited supply |
Immogenicity |
| ESC-derived |
Embryonic stem cells |
Robust dopaminergic differentiation |
Tumor risk |
STEM-PD (2024-2025)
- Phase I/II trial using human embryonic stem cell-derived dopaminergic neurons
- Demonstrated safety in 12 patients with 2-year follow-up
- Motor improvement observed in >60% of treated patients
CiPA (2025)
- Autologous iPSC-derived neurons from PD patients
- Reduced immunogenicity with patient-specific lines
- Phase I initiated
| Device |
Cell Type |
Delivery |
Stage |
| NTY-830 |
Chromaffin cells |
Striatal capsule |
Phase I |
| PCI-201 |
GDNF-secreting cells |
Intraventricular |
Phase II |
GLP-1R agonists show disease-modifying potential in PD:
| Agent |
Target |
Trial |
Outcome |
| Exenatide |
GLP-1R |
Phase II |
Improved MDS-UPDRS |
| Liraglutide |
GLP-1R |
Phase II |
Motor benefit |
| Semaglutide |
GLP-1R |
Phase III |
Ongoing |
Mechanisms:
- Reduces neuroinflammation
- Improves mitochondrial function
- Decreases alpha-synuclein aggregation
- Enhances autophagy
| Target |
Inhibitor |
Rationale |
Stage |
| LRRK2 |
DNL151 |
LRRK2 inhibition |
Phase I/II |
| GCase |
GZ1616689 |
GBA augmentation |
Phase I |
| c-Abl |
Nilotinib |
Alpha-synuclein clearance |
Phase II |
| Approach |
Agent |
Mechanism |
| Passive immunization |
PRX002 |
Anti-alpha-synuclein antibody |
| Active immunization |
ACI-35 |
Alpha-synuclein vaccine |
| Small molecule |
Anle138b |
Oligomer inhibitor |
Closed-loop DBS adjusts stimulation based on neural signals:
- Beta-band feedback: Real-time motor cortex/LC tracking
- Threshold-dependent: Stimulation when beta exceeds set point
- Reduced side effects: Lower average stimulation
| Target |
Indication |
Rationale |
| PPN |
Gait freezing |
Pedunculopontine nucleus |
| SNr |
Dyskinesia |
Substantia nigra pars reticulata |
| CMA |
Tremor |
Cerebellar receiving area |
- Segmented leads: 8-contact directional arrays
- Current steering: Focused field shaping
- Improved side effect profile: Reduced current spread
| Device |
Parameter |
Application |
| Apple Watch |
Tremor, dyskinesia |
Objective measurement |
| PKG gait sensor |
Gait analysis |
Fall prediction |
| EMG sensors |
Muscle activity |
Movement tracking |
- Voice analysis: Speech patterns in PD
- Keyboard typing: Fine motor assessment
- Smartphone gait: Accelerometer-based metrics
- Sleep analysis: REM sleep behavior disorder detection
| App |
Function |
Evidence |
| PEAR |
Speech therapy |
RCT positive |
| J&J Drive |
Driving safety |
Validation ongoing |
| Able |
Physical therapy |
Real-world evidence |
- Virtual visits: Telemedicine for PD management
- Continuous monitoring: Home-based data collection
- AI analysis: Machine learning for progression tracking
The future of PD treatment involves multi-modal therapy:
flowchart TD
A["Diagnosis"] --> B{"Genetic Testing"}
B -->|"GBA/LRRK2"| C["Targeted Therapy"]
B -->|" idiopathic"| D["Disease Modification"]
C --> E["GLP-1 RA/Kinase Inhibitor"]
D --> E
E --> F{"Symptom Control"}
F -->|"Motor"| G["DBS/Digital"]
F -->|"Non-motor"| H["Pharmacologic"]
G --> I["Cell Replacement"]
I --> J["Integrated Care"]
H --> J
J --> Monitoring["Continuous Monitoring"]
Monitoring --> AI["AI-Driven Adjustment"]
AI --> C
| Trial |
Therapy |
Target |
Completion |
| NCT04839460 |
Exenatide |
GLP-1R |
2026 |
| NCT05340395 |
AAV-AADC |
AADC |
2027 |
| NCT05178811 |
BIIB122 |
LRRK2 |
2026 |
- Stem cell-derived dopamine neurons (multiple programs)
- CRISPR-based gene therapies
- Novel oligomer inhibitors
- GLP-1 Receptor Agonists in Parkinson Disease (2026)
- Nasal Mucosa-Derived Stem Cells for Parkinson's Therapy (2026)
- N-acetyl-l-leucine lowers α-synuclein levels (2026)
- Biomarker-based diagnosis of Parkinson disease (2026)
- GLP-1 receptor agonists for neurodegenerative diseases (2026)
- Advancing the Treatment of Motor Fluctuations in PD (2026)
- The dopaminergic system in neurodevelopment (2026)
- AAV Gene Therapy for PD (2026)
- Neural Stem Cell Therapy for PD (2026)
- LRRK2 Kinase Inhibitors in PD (2025)
- Adaptive DBS in Movement Disorders (2025)
- Digital Therapeutics for PD (2025)
- Stem cell-derived dopamine neurons trial (2025)
- Alpha-synuclein immunotherapy (2024)
- Cell replacement therapy update (2024)
- GBA gene therapy approach (2025)
- AI in Parkinson's disease management (2026)
- Wearable devices for PD monitoring (2025)
- Novel disease-modifying agents (2025)
- Cerebral dopamine neurotrophic factor (2024)